Apomorphine in advanced Parkinson disease
Apomorphine is the most potent dopamine receptor agonist and its symptomatic effectiveness is comparable to levodopa. Subcutaneous apomorphine is rapidly and completely absorbed. Plasma peak concentrations are achieved after 5-15 minutes and onset of clinical effect is within 20 minutes. Apomorphine intermittent subcutaneous injections are effective as rescue therapy for unpredictable off periods in advanced Parkinson disease (PD). More often apomorphine is administered as a subcutaneous infusion which secures the continuous dopaminergic stimulation. The benefit on 'off' periods is consistent across all studies, but dyskinesia improvement is not so obvious. Two infusion therapies (apomorphine and intraduodenal levodopa) and deep brain stimulation (DBS) are effective in advanced PD patients with untreatable motor complications. Apomorphine infusions should be considered in patients unable to undergo DBS because of cognitive impairment and neurosurgical contraindications.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Neurologia i neurochirurgia polska - 47(2013), 5 vom: 21. Sept., Seite 476-83 |
| Sprache: |
Polnisch |
|---|
| Weiterer Titel: |
Apomorfina w zaawansowanej chorobie Parkinsona |
|---|
| Beteiligte Personen: |
Bogucki, A [VerfasserIn] |
|---|
| Themen: |
Antiparkinson Agents |
|---|
| Anmerkungen: |
Date Completed 17.01.2014 Date Revised 12.11.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM232070091 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM232070091 | ||
| 003 | DE-627 | ||
| 005 | 20231224092158.0 | ||
| 007 | tu | ||
| 008 | 231224s2013 xx ||||| 00| ||pol c | ||
| 028 | 5 | 2 | |a pubmed24n0773.xml |
| 035 | |a (DE-627)NLM232070091 | ||
| 035 | |a (NLM)24166569 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a pol | ||
| 100 | 1 | |a Bogucki, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Apomorphine in advanced Parkinson disease |
| 246 | 3 | 3 | |a Apomorfina w zaawansowanej chorobie Parkinsona |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2014 | ||
| 500 | |a Date Revised 12.11.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Apomorphine is the most potent dopamine receptor agonist and its symptomatic effectiveness is comparable to levodopa. Subcutaneous apomorphine is rapidly and completely absorbed. Plasma peak concentrations are achieved after 5-15 minutes and onset of clinical effect is within 20 minutes. Apomorphine intermittent subcutaneous injections are effective as rescue therapy for unpredictable off periods in advanced Parkinson disease (PD). More often apomorphine is administered as a subcutaneous infusion which secures the continuous dopaminergic stimulation. The benefit on 'off' periods is consistent across all studies, but dyskinesia improvement is not so obvious. Two infusion therapies (apomorphine and intraduodenal levodopa) and deep brain stimulation (DBS) are effective in advanced PD patients with untreatable motor complications. Apomorphine infusions should be considered in patients unable to undergo DBS because of cognitive impairment and neurosurgical contraindications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antiparkinson Agents |2 NLM | |
| 650 | 7 | |a Apomorphine |2 NLM | |
| 650 | 7 | |a N21FAR7B4S |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Neurologia i neurochirurgia polska |d 1967 |g 47(2013), 5 vom: 21. Sept., Seite 476-83 |w (DE-627)NLM000008524 |x 0028-3843 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2013 |g number:5 |g day:21 |g month:09 |g pages:476-83 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2013 |e 5 |b 21 |c 09 |h 476-83 | ||